Astrazeneca (AZN) Liabilities and Shareholders Equity (2009 - 2026)
Astrazeneca (AZN) posted quarterly Liabilities and Shareholders Equity of $115.8 billion for Q2 2026, up 3.03% year-over-year from $112.4 billion in Q2 2025, and up 1.59% quarter-over-quarter from $114.0 billion in Q1 2026.
Astrazeneca (AZN) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Astrazeneca's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $115.8 billion for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 3.03% year-over-year to $115.8 billion; the TTM figure through Jun 2026 stood at $458.4 billion (up 7.19% YoY), while the FY2025 annual figure was $114.1 billion, up 9.65% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $115.8 billion, up from $114.0 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $115.8 billion in Q2 2026, with the low at $313.0 million in Q4 2023.
- The 5-year median for Liabilities and Shareholders Equity is $103.2 billion (2024), against an average of $98.3 billion.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 92672.12% in 2022, then sank 99.68% in 2023.
- Astrazeneca's Liabilities and Shareholders Equity stood at $96.5 billion in 2022, then tumbled by 99.68% to $313.0 million in 2023, then surged by 33138.02% to $104.0 billion in 2024, then rose by 9.65% to $114.1 billion in 2025, then gained by 1.54% to $115.8 billion in 2026.
- Business Quant data shows AZN's Liabilities and Shareholders Equity at $115.8 billion in Q2 2026, $114.0 billion in Q1 2026, and $114.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.83 Bn |
| Mar 31, 2026 | 114.02 Bn |
| Dec 31, 2025 | 114.07 Bn |
| Sep 30, 2025 | 114.46 Bn |
| Jun 30, 2025 | 112.42 Bn |
| Mar 31, 2025 | 106.25 Bn |
| Dec 31, 2024 | 104.04 Bn |
| Sep 30, 2024 | 104.92 Bn |
| Jun 30, 2024 | 104.34 Bn |
| Mar 31, 2024 | 102.29 Bn |
| Dec 31, 2023 | 313.00 Mn |
| Sep 30, 2023 | 96.09 Bn |
| Jun 30, 2023 | 96.54 Bn |
| Mar 31, 2023 | 96.69 Bn |
| Dec 31, 2022 | 96.48 Bn |
| Sep 30, 2022 | 94.19 Bn |
| Jun 30, 2022 | 96.58 Bn |
| Mar 31, 2022 | 100.27 Bn |
| Dec 31, 2021 | 104.00 Mn |
| Sep 30, 2021 | 107.22 Bn |